Articles tagged "Tolerance"

2017 American Transplant Congress
PTEN Inhibition in MSC Upregulates PD-L1 and Enhances Their Immunomodulatory Capacity Prolonging Skin Allograft Survival.
M. Climov, M. Uehara, Z. Solhjou, H. Matsumine, N. Bouyani, E. Kefaloyianni, B. Basmani, V. Kasinath, G. Giatsidis, D. Orgill, R. Abdi.
Brigham and Women's Hospital, Boston, MA
Due to lack of autologous and donor site morbidity, there is a distinct clinical need to increase the utility of skin allografts by improving their…
2017 American Transplant Congress
A Clinically Relevant Protocol for Vascularized Composite Allotransplantation Using a Single Dose of AMD3100 for Stem Cell Mobilization.
B. Swearingen,^1,2 S. Graves,^2,3 R. Storb,^2,3 D. Mathes.^1,2
¹Surgery, Division of Plastic and Reconstructive Surgery, University of Colorado School of Medicine, Aurora, CO; ²Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA; ³Medicine, University of Washington Medical Center, Seattle, WA
BACKGROUND: Vascularized Composite Allograft (VCA) transplantation is a clinical reality but application is limited by toxicities of chronic immunosuppression and rejection. Current clinical tolerance protocols…
2017 American Transplant Congress
The Intragraft Vascularized Bone Marrow Component and Recipient T Regulatory Cells Facilitate Tolerance Induction After Post Transplant High Dose Cyclophosphamide Treatment in VCA.
G. Furtmüller, B. Oh, M. Fryer, S. Ganguly, V. Malek, X. Zhou, J. Dodd-o, G. Raimondi, D. Cooney, C. Brayton, W. Lee, L. Luznik, G. Brandacher.
Johns Hopkins University School of Medicine, Baltimore, MD
Background: VCA is a viable treatment option for devastating tissue defects. However, the life-long need for immunosuppression curtails the wider use of VCA. Unique VCA-features…
2017 American Transplant Congress
Autotransplantation of the Left Lung for the Treatment of Recurrent Life Threatening Pulmonary Hemorrhage Related to Pulmonary Vascular Malformation: A Unique Chance to Study Ischemia/Reperfusion Injury.
C. Falk,¹ I. Tudorache,² C. Müller,³ W. Sommer,² K. Daemen,¹ J. Keil,¹ G. Hansen,³ A. Haverich,² G. Warnecke,² N. Schwerk.³
¹Institute of Transplant Immunology, IFB-Tx, MHH, Hannover, Germany; ²Department of Cardiothoracic Transplant and Vascular Surgery, MHH, Hannover, Germany; ³Department of Pediatric Pneumology, MHH, Hannover, Deutschland, Germany
Background: Ischemia reperfusion injury (IRI) remains a major clinical problem in lung transplantation. Here, we report the investigation of IRI in a 17-year-old patient who…
2016 American Transplant Congress
Indefinite Survival of Fully MHC-Mismatched Murine Cardiac Allografts by Combination of Anti-BTLA mAb (6B2) and Anti-PD-1 mAb (PIM-2).
E. Yin,^1,2 M. Uchiyama,^1,3 X. Jin,^1,4 T. Shimokawa,³ H. Yagita,⁵ M. Niimi.¹
¹Surgery, Teikyo University, Tokyo, Japan; ²Cardiovascular Surgery, The 2nd Affiliated Hospital of Harbin Medical University, Harbin, China; ³Cardiovascular Surgery, Teikyo University, Tokyo, Japan; ⁴Thoracic Surgery, The 3rd Affiliated Hospital of Harbin Medical University, Harbin, China; ⁵Immunology, Juntendo University Hospital, Tokyo, Japan.
Background: The co-inhibitory receptor B and T lymphocyte attenuator (BTLA) and Programmed death (PD)-1 had been suggested to have immunomodulatory activity. This study investigated the…
2016 American Transplant Congress
Immune Tolerance Monitoring in Renal Allograft Tolerance Induced by Transient Mixed Chimerism in Nonhuman Primates and Humans.
K. Hotta, T. Oura, K. Crisalli, D. Sachs, B. Cosim, T. Kawai.
Center for Transplantation Science, Massachusetts General Hospital, Boston, MA.
Background: Successful induction of allograft tolerance in MHC-mismatched kidney transplantation has been achieved after induction of transient chimerism in both nonhuman primates (NHP) and humans.…
2016 American Transplant Congress
Results of a Phase 1 Trial of Treg Adoptive Cell Transfer (TRACT) in De Novo Living Donor Kidney Transplant Recipients.
A. Skaro,¹ A. LeFever,² J. Mathew,¹ L. Gallon,¹ J. Hie,¹ C. Hansen,² D. Stare,¹ G. Johnson,³ J. Leventhal.¹
¹Northwestern University, Chicago; ²NMH, Chicago; ³TRACT Therapeutics, Chicago.
Therapeutic cell transfer using regulatory T cells (Tregs) holds the promise of reducing the need for drug based immunosuppression (IS) and improving long term graft…
2016 American Transplant Congress
The Role of PI3kγ and PI3kδ in Alloimmunity.
M. Uehara,¹ A. Jamil,¹ Z. Solhjou,¹ M. McGrath,¹ N. Banouni,¹ C. Evans,² J. Dinitto,² D. Winkler,² R. Abdi.¹
¹Transplantation Research Center, Renal Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; ²Infinity Pharmaceuticals, Inc, Boston.
We studied the role of phosphatidylinositol-3-kinases (PI3k) γ and δ pathway in alloimmunity. Generated Foxp3-GFP-PI3kγ and -PI3kδ knockout mice (C57BL/6 background) were used in heart…
2016 American Transplant Congress
Recapitulating Peripheral T Cell Development in Neonatal Mice to Induce Transplant Tolerance.
R. Bascom, K. Tao, L. West.
University of Alberta, Edmonton, Canada.
Purpose: Neonatal mice are susceptible to tolerance induction with semi-allogeneic bone marrow and spleen cells (BMC/SC) while allogeneic BMC/SC cause acute lethal graft-versus-host disease (GVHD).…
2016 American Transplant Congress
IL-10 Expression of In Vitro Activated B Cells as A Biomarker for B Cell Tolerance.
T. Oura, K. Hotta, K. Crisalli, B. Cosimi, T. Kawai.
Center for Transplantation Sciences, Massachusetts General Hospital, Boston, MA.
Background: A significant role for regulatory B cell has been suggested in kidney transplant recipients who achieved operational tolerance while receiving conventional immunosuppression. We studied…